We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.75 | -1.78% | 41.50 | 41.00 | 42.00 | 42.25 | 41.25 | 42.25 | 103,886 | 12:11:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Misc Retail Stores, Nec | 43.98M | 520k | 0.0041 | 101.22 | 52.22M |
From Apr 2019 to Apr 2024
TIDMVLG
RNS Number : 9663F
Venture Life Group PLC
23 May 2017
Venture Life Group plc
("Venture Life" or the "Company")
Result of AGM
Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
For further information please contact:
Hot Features
Premium
Venture Life Group PLC +44 (0) 1344 742870
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited (Nominated Adviser +44 (0) 20 3861
and Joint Broker) 6625
Matthew Johnson / Edward Hutton / Margarita Mitropoulou
(Corporate Finance)
Bob Pountney / John Howes (Corporate Broking)
+44 (0) 20 3621
Turner Pope Investments (TPI) Ltd (Joint Broker) 4120
James Pope / Ben Turner
Walbrook PR venturelife@walbrookpr.com or + 44 (0) 20
7933 8780
Anna Dunphy / Paul McManus +44 (0) 7980 541 893 / +44 (0) 7876 741
001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.
Through its development and manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGUOVKRBKAVURR
(END) Dow Jones Newswires
May 23, 2017 05:59 ET (09:59 GMT)
1 Year Venture Life Chart |
1 Month Venture Life Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
